• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
News and impact
NIHR Biomedical Research Centre Leicester

NIHR Biomedical Research Centre Leicester

  • Home
  • About Us
    • Leadership Team
    • Our Impact
    • Our NIHR infrastructure
    • Governance
    • Inclusion
    • Strategies
    • Contact us
  • Our Research
    • Our Impact
    • Spotlight on our researchers
    • Cardiovascular
    • Data Innovation for Multiple Long-Term Health Conditions and Ethnic Health
    • Environment
    • Lifestyle
    • Personalised Cancer Prevention and Treatment
    • Respiratory and Infection
  • Patients and Public
    • Get Involved
    • Upcoming Public Involvement opportunities
    • Our approach to Public Involvement
    • Join the BioResource and Be Part of Research
    • Taking part in Clinical Trials
  • Industry and Partners
    • What we offer to industry
    • Collaborate with the Leicester BRC
    • Our partnerships
      • The NIHR Diet and Activity Research Translation (DART) Collaboration
  • For Researchers
    • Training
    • The Internal Resource Hub
    • Acknowledging and communicating your research
    • Guidance on Public Involvement (PPIE) for researchers
    • Advancing inclusion: transforming research culture in Leicester and beyond
    • PPI for Statistical Methodology and Research Techniques
  • News and Impact

New treatment offers hope for patients with heart failure

Nov 7, 2017

Leicester’s first His bundle pacemaker, a pioneering new technique, has been implanted at Leicester’s Hospitals.

The procedure was carried out as part of the HOPE-HF clinical trial and was performed by consultant cardiologists, Professor Andre Ng from the University of Leicester and Dr Ravi Pathmanathan from Leicester’s Hospitals.

The technique involves placing an extra pacemaker lead into the heart to correct the delay in onset of electrical activation within the heart.

Heart failure is a serious clinical problem, which often causes severe symptoms. Cardiac Resynchronisation therapy (CRT) is a type of pacemaker therapy used in patients with the condition.

However, it is only effective in patients who have a disturbance in the electrical activation of the main pumping chamber (ventricle) of the heart (‘left bundle branch block’).

Some patients with heart failure have normal activation of the ventricles, but the onset of activation is delayed. This is called ‘PR interval prolongation’.

These patients also have a higher risk of developing heart failure symptoms and death but do not benefit from CRT pacemakers currently. Direct His bundle pacing can correct the delay in the onset of activation of the heart and improve symptoms. Early studies have shown very promising results.

X-ray image taken during procedure with the standard pacemaker and ICD leads together with the additional new His-bundle lead (arrow)

The multicentre HOPE-HF clinical trial will test the new treatment in this group of patients with ‘PR interval prolongation’, who are not currently offered pacing therapy to treat their heart failure.

Award-winning University of Leicester Professor of Cardiac Electrophysiology, Andre Ng, said: “If the treatment is found to be effective, this would be an exciting advance, as it would mean we have a new treatment for a group of patients with heart failure. These patients are often very limited by their symptoms and therefore a new treatment which reduces symptoms would be very important.”

The procedure has attracted much enthusiasm amongst the cardiology team at Glenfield, which is one of the largest cardiac centres in the UK and has been at the forefront of a number of innovations.

The technique to implant a His bundle pacemaker requires very little additional training and uses equipment and devices already available on the shelf. The procedure takes less time to perform than the current pacemakers (CRT) used for heart failure.
In the current climate of austerity, these features add significant value to the new technique.

The trial is funded by the British Heart Foundation, led by Imperial College, and being supported by Leicester’s new NIHR Biomedical Research Centre.

Ends

 

Category: Press ReleasesTag: Press Release

Recent News

Leicester health specialists receive NIHR prizes for excelling in their fields

Respiratory researcher awarded Asthma + Lung UK Junior Fellowship

Weight-loss drug users turn to social media over doctors for advice

Read more news stories

The NIHR Leicester BRC is part of the NIHR and hosted by the University Hospitals of Leicester NHS Trust in partnership with the University of Leicester,  Loughborough University and the University Hospitals of the Northamptonshire NHS Group.

Get in touch

NIHR Leicester Biomedical Research Centre

University Hospitals of Leicester NHS Trust
Research & Innovation
Leicester General Hospital
Gwendolen Road
Leicester, LE5 4PW

Contact us

Our Research

Spotlight on our researchers

Cardiovascular

Data Innovation for Multiple Long-Term Health Conditions and Ethnic Health

Environment

Personalised Cancer Prevention and Treatment

Lifestyle

Respiratory and Infection

About BRC

Our NIHR infrastructure

BRC clinical research during COVID-19

Our 2022 – 2028 strategy documents

Governance

Useful links

Our partnerships

Inclusion

Privacy notice

Cookie Policy

Copyright © NIHR Biomedical Research Centre: Leicester

  • LinkedIn
  • X
  • Facebook
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}